501 related articles for article (PubMed ID: 32462119)
21. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong GLH; Gane E; Lok ASF
J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
[TBL] [Abstract][Full Text] [Related]
22. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
23. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Chien RN; Liaw YF
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
[TBL] [Abstract][Full Text] [Related]
24. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.
Suzuki F; Miyakoshi H; Kobayashi M; Kumada H
J Med Virol; 2009 Jan; 81(1):27-33. PubMed ID: 19031469
[TBL] [Abstract][Full Text] [Related]
25. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
[TBL] [Abstract][Full Text] [Related]
26. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
27. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
28. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA.
Liu YY; Liang XS
World J Hepatol; 2018 Sep; 10(9):603-611. PubMed ID: 30310538
[TBL] [Abstract][Full Text] [Related]
29. The Role of Hepatitis B Core-Related Antigen.
Inoue T; Tanaka Y
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31075974
[TBL] [Abstract][Full Text] [Related]
30. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
31. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2021 Nov; 5(11):1873-1887. PubMed ID: 34558823
[TBL] [Abstract][Full Text] [Related]
32. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B.
Azhari H; Frolkis AD; Shaheen AA; Israelson H; Pinto J; Congly SE; Borman MA; Aspinall AA; Stinton LM; Nguyen HH; Swain MG; Burak KW; Lee SS; Sadler MD; Coffin CS
Can Liver J; 2022 Nov; 5(4):453-465. PubMed ID: 38144400
[No Abstract] [Full Text] [Related]
33. Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis.
Villeret F; Lebossé F; Radenne S; Samuel D; Roche B; Mabrut JY; Leroy V; Pageaux GP; Anty R; Thevenon S; Ahmed SS; Hamilton A; Heil M; Scholtès C; Levrero M; Testoni B; Zoulim F;
JHEP Rep; 2023 Jun; 5(6):100728. PubMed ID: 37122357
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
[TBL] [Abstract][Full Text] [Related]
35. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
[TBL] [Abstract][Full Text] [Related]
36. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA.
Chen EQ; Wang ML; Tao YC; Wu DB; Liao J; He M; Tang H
J Viral Hepat; 2019 May; 26(5):586-595. PubMed ID: 30632235
[TBL] [Abstract][Full Text] [Related]
37. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.
Wu Y; Wen J; Tang G; Zhang J; Xin J
J Infect; 2021 Nov; 83(5):594-600. PubMed ID: 34474058
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
[TBL] [Abstract][Full Text] [Related]
39. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
Liaw YF; Chien RN
Kaohsiung J Med Sci; 2022 Apr; 38(4):295-301. PubMed ID: 35262284
[TBL] [Abstract][Full Text] [Related]
40. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
